KZRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:51):

Stats
本日の出来高	323 613
平均出来高	775 175
時価総額	61.12M
EPS	$0 ( 2024-03-12 )
次の収益日	( $-0.330 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.00300 (0.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-15	Schiller Mark C.	Sell	0	Common Stock
2024-01-15	Schiller Mark C.	Sell	165 000	Employee Stock Option (right to buy)
2024-01-15	Schiller Mark C.	Sell	250 000	Employee Stock Option (right to buy)
2024-01-07	Belsky Marc	Buy	295 000	Employee Stock Option (right to buy)
2024-01-07	Mordwinkin Nicholas Michael	Buy	275 000	Employee Stock Option (right to buy)

INSIDER POWER
-14.21
Last 100 transactions
Buy: 7 465 931 \| Sell: 10 295 837

ボリューム相関

長: 0.08 (neutral)

短: -0.31 (neutral)

Signal:(52.435) Neutral

Kezar Life Sciences Inc 相関

10 最も正の相関
CMLS	0.976
AROW	0.974
ESSA	0.973
BSRR	0.973
ISTR	0.973
AADI	0.972
CPTN	0.972
MOFG	0.972
BCBP	0.972
CBAN	0.969

10 最も負の相関
SGEN	-0.959
TZPS	-0.957
RPHM	-0.954
LMB	-0.95
PESI	-0.944
MLAI	-0.941
RAM	-0.941
GPACU	-0.939
COCO	-0.939
AMPH	-0.938

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kezar Life Sciences Inc 相関 - 通貨/商品

0.00
( neutral )

-0.16
( neutral )

0.00
( neutral )

-0.19
( neutral )

Kezar Life Sciences Inc 財務諸表

Annual	2023
収益:	$7.00M
総利益:	$5.93M (84.77 %)
EPS:	$-1.400

FY	2023
収益:	$7.00M
総利益:	$5.93M (84.77 %)
EPS:	$-1.400

FY	2022
収益:	$0
総利益:	$-1.02M (0.00 %)
EPS:	$-0.970

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00102

Financial Reports:

No articles found.

Kezar Life Sciences Inc

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.